SG11201811831SA - Compositions and methods for stabilizing flaviviruses with improved formulations - Google Patents
Compositions and methods for stabilizing flaviviruses with improved formulationsInfo
- Publication number
- SG11201811831SA SG11201811831SA SG11201811831SA SG11201811831SA SG11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA
- Authority
- SG
- Singapore
- Prior art keywords
- urea
- sucrose
- trehalose
- msg
- alanine
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370611P | 2016-08-03 | 2016-08-03 | |
| PCT/US2017/045375 WO2018027075A1 (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811831SA true SG11201811831SA (en) | 2019-01-30 |
Family
ID=59593235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811831SA SG11201811831SA (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
| SG10201913040SA SG10201913040SA (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913040SA SG10201913040SA (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10835597B2 (https=) |
| EP (1) | EP3493839A1 (https=) |
| JP (2) | JP7280179B2 (https=) |
| KR (2) | KR20230132887A (https=) |
| CN (1) | CN109789200A (https=) |
| AU (2) | AU2017305498B2 (https=) |
| CA (1) | CA3030343A1 (https=) |
| CO (1) | CO2019001448A2 (https=) |
| MX (2) | MX2019001473A (https=) |
| PH (1) | PH12019500003A1 (https=) |
| SG (2) | SG11201811831SA (https=) |
| TW (2) | TW202309276A (https=) |
| WO (1) | WO2018027075A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| CR20190291A (es) * | 2016-12-23 | 2019-11-05 | Serum Institute Of India Pvt Ltd | Métodos mejorados para estimular la productividad de anticuerpos en el cultivo de células de mamiferos y reducir la agregación durante los procesos de formulación post-tratamiento (downstream) y formulaciones de anticuerpos estables obtenidas a partir de los mismos |
| WO2019112921A1 (en) | 2017-12-07 | 2019-06-13 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| CA3094404A1 (en) * | 2018-03-20 | 2019-09-26 | National Research Council Of Canada | A method for lyophilizing live vaccine strains of francisella tularensis |
| KR102646145B1 (ko) | 2018-05-31 | 2024-03-11 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
| KR102058961B1 (ko) | 2018-07-28 | 2019-12-24 | 주식회사 엑소코바이오 | 엑소좀의 동결건조 방법 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| KR20210100662A (ko) * | 2018-12-05 | 2021-08-17 | 세레스 테라퓨틱스, 인코포레이티드 | 박테리아를 안정화시키는 조성물 그리고 이의 용도 |
| BR112022001476A2 (pt) | 2019-08-16 | 2023-10-03 | Takeda Vaccines Inc | Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit |
| BR112022015710A2 (pt) * | 2020-02-27 | 2022-09-27 | Takeda Vaccines Inc | Método para remover dna de célula hospedeira a partir da preparação de vírus |
| CN115023135B (zh) * | 2020-02-28 | 2024-04-19 | 台湾粒线体应用技术股份有限公司 | 线粒体的冷冻保存剂与使用其的线粒体冷冻保存方法 |
| CN113549653B (zh) * | 2020-04-23 | 2024-03-22 | 上海赛比曼生物科技有限公司 | 用于慢病毒载体长期存贮的组合试剂 |
| CN111588859B (zh) * | 2020-06-02 | 2021-09-03 | 成都可恩生物科技有限公司 | 一种冻干保护剂及其应用和冻干苗及其制备方法 |
| CN112501024A (zh) * | 2020-12-03 | 2021-03-16 | 英科新创（苏州）生物科技有限公司 | 一种体外诊断试剂盒通用型质控品保存液 |
| EP4012025A1 (en) * | 2020-12-10 | 2022-06-15 | Univerzita Palackého v Olomouci | Transport medium for samples containing nucleic acids and/or proteins |
| CN113730592B (zh) * | 2021-09-03 | 2023-12-19 | 吉林正业生物制品股份有限公司 | 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 |
| EP4356925B1 (en) * | 2022-10-18 | 2025-09-10 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
| WO2025027616A1 (en) * | 2023-08-01 | 2025-02-06 | Serum Institute Of India Private Limited | Freeze-dried viral vaccine compositions and method of manufacturing thereof |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122946A1 (en) * | 2023-12-07 | 2025-06-12 | Rovin Richard A | Zika viruses and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| MX2009004862A (es) * | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| WO2009014774A1 (en) * | 2007-04-06 | 2009-01-29 | Inviragen, Inc. | Methods and compositions for live attenuated viruses |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| JP2019511533A (ja) * | 2016-04-13 | 2019-04-25 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 |
-
2017
- 2017-08-02 TW TW111118644A patent/TW202309276A/zh unknown
- 2017-08-02 TW TW106126119A patent/TWI766876B/zh active
- 2017-08-03 US US16/322,791 patent/US10835597B2/en active Active
- 2017-08-03 WO PCT/US2017/045375 patent/WO2018027075A1/en not_active Ceased
- 2017-08-03 KR KR1020237030300A patent/KR20230132887A/ko not_active Withdrawn
- 2017-08-03 JP JP2019505214A patent/JP7280179B2/ja active Active
- 2017-08-03 CN CN201780047777.5A patent/CN109789200A/zh active Pending
- 2017-08-03 MX MX2019001473A patent/MX2019001473A/es unknown
- 2017-08-03 AU AU2017305498A patent/AU2017305498B2/en active Active
- 2017-08-03 KR KR1020197005623A patent/KR102576789B1/ko active Active
- 2017-08-03 SG SG11201811831SA patent/SG11201811831SA/en unknown
- 2017-08-03 SG SG10201913040SA patent/SG10201913040SA/en unknown
- 2017-08-03 CA CA3030343A patent/CA3030343A1/en active Pending
- 2017-08-03 EP EP17751959.2A patent/EP3493839A1/en active Pending
-
2019
- 2019-01-03 PH PH12019500003A patent/PH12019500003A1/en unknown
- 2019-02-01 MX MX2022010907A patent/MX2022010907A/es unknown
- 2019-02-19 CO CONC2019/0001448A patent/CO2019001448A2/es unknown
-
2020
- 2020-10-05 US US17/062,923 patent/US11701421B2/en active Active
-
2023
- 2023-01-25 JP JP2023009386A patent/JP2023052624A/ja active Pending
- 2023-02-23 US US18/113,193 patent/US20230263880A1/en active Pending
- 2023-06-14 AU AU2023203715A patent/AU2023203715A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230263880A1 (en) | 2023-08-24 |
| BR112019001299A2 (pt) | 2019-04-30 |
| AU2017305498B2 (en) | 2023-03-30 |
| JP7280179B2 (ja) | 2023-05-23 |
| CN109789200A (zh) | 2019-05-21 |
| KR102576789B1 (ko) | 2023-09-12 |
| AU2017305498A1 (en) | 2019-01-24 |
| MX2019001473A (es) | 2019-09-23 |
| JP2019524771A (ja) | 2019-09-05 |
| US20190184004A1 (en) | 2019-06-20 |
| WO2018027075A1 (en) | 2018-02-08 |
| US10835597B2 (en) | 2020-11-17 |
| KR20190034598A (ko) | 2019-04-02 |
| CA3030343A1 (en) | 2018-02-08 |
| TW201807191A (zh) | 2018-03-01 |
| PH12019500003A1 (en) | 2019-10-14 |
| JP2023052624A (ja) | 2023-04-11 |
| AU2023203715A1 (en) | 2023-07-06 |
| TWI766876B (zh) | 2022-06-11 |
| US11701421B2 (en) | 2023-07-18 |
| MX2022010907A (es) | 2022-10-07 |
| SG10201913040SA (en) | 2020-03-30 |
| CO2019001448A2 (es) | 2019-04-30 |
| EP3493839A1 (en) | 2019-06-12 |
| US20210121558A1 (en) | 2021-04-29 |
| TW202309276A (zh) | 2023-03-01 |
| KR20230132887A (ko) | 2023-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811831SA (en) | Compositions and methods for stabilizing flaviviruses with improved formulations | |
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201803073TA (en) | Insect singulator system | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201907891XA (en) | Combination therapy for the treatment or prevention of tumours | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201807003UA (en) | Smc combination therapy for the treatment of cancer | |
| SG11201900028VA (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201808479VA (en) | Live, attenuated alphavirus constructs and methods and uses thereof | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201907442UA (en) | METHODS FOR INCREASING BLOOD PLASMA 2'-DEOXYURIDINE (dUrd) AND THYMIDYLATE SYNTHASE INHIBITION |